Lawver’s position oversees the global commercial organization at the continuous glucose monitoring (CGM) technology developer. She holds responsibility for global sales, marketing and customer experience.
Before joining San Diego-based Dexcom, Lawver spent two decades in a variety of leadership roles at Johnson & Johnson. Her positions spanned the medical device, consumer medtech and pharmaceutical sectors. Most recently, she served as worldwide VP, immunology at J&J’s Janssen Pharmaceutical Companies.
“I am thrilled to join Dexcom in the new chief commercial officer role and guide our talented team at this exciting time in the company’s history,” Lawver said.
Dexcom also today shared preliminary results for the fourth quarter ended Dec. 31, 2022. It expects at least $815 million in revenue, representing a 17% increase year-over-year. That includes U.S. revenues expected to total approximately $606 million. Analysts projected $807.7 million in sales for the quarter.
Get the full story at our sister site, Drug Delivery Business News.